LYCOS RETRIEVER 
King Pharmaceuticals: United States
built 630 days ago
On February 28, 2007, King Pharmaceuticals, Inc. issued a press release announcing its results of operations for the year and quarter ended December 31, 2006. A copy of the press release is attached hereto as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits.
Source:
Mylan, King and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Mylan and King in favor of the acquisition. Information about the executive officers and directors of Mylan and their ownership of Mylan common stock is set forth in the proxy statement for Mylan's 2004 Annual Meeting of Shareholders, which was filed with the SEC on June 28, 2004. Information about the executive officers and directors of King and their ownership of King common stock is set forth in the proxy statement for King's 2003 Annual Meeting of Shareholders, which was filed with the SEC on September 19, 2003. Investors and shareholders may obtain more detailed information regarding the direct and indirect interests of Mylan, King and their respective executive officers and directors in the acquisition by reading the joint proxy statement/prospectus regarding the acquisition, which is included in the Registration Statement on Form S-4 filed by Mylan with the SEC on September 3, 2004.
Source:
King's Meridian segment ... includes pharmaceutical products that are sold primarily to the United States Department of Defense (DoD),, under an Industrial Base Maintenance Contract, which is terminable by the DoD at its convenience. These products include the nerve agent antidotes AtroPen and ComboPen, and the Antidote Treatment Nerve Agent Auto-injector (ATNAA). AtroPen is an atropine-filled, auto-injector and ComboPen consists of an atropine-filled, auto-injector and a pralidoxime-filled, auto-injector. The ATNAA utilizes a dual chambered auto-injector and injection process to administer atropine and pralidoxime, providing a means of delivering these nerve agent antidotes. Other products sold to the DoD also include a diazepam-filled auto-injector for the treatment of seizures and a morphine-filled auto-injector for pain management.
Source:
MORE ABOUT
United States